

1. Record Nr.	UNINA9910830390303321
Titolo	Pharmacogenomics [[electronic resource]] : the search for individualized therapies / / edited by Julio Licinio and Ma-Li Wong
Pubbl/distr/stampa	Weinheim ; ; [Chichester?], : Wiley-VCH, c2002
ISBN	9786612278976 1-282-27897-5 3-527-61630-6 1-280-55845-8 9786610558452 3-527-60075-2
Descrizione fisica	1 online resource (601 p.)
Altri autori (Persone)	LicinioJ WongMa-Li
Disciplina	615.1 615.19 615.7
Soggetti	Pharmacogenomics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Pharmacogenomics The Search for Individualized Therapies; Acknowledgements; Preface; Contents; List of Contributors; Color Plates; 1 Introduction to Pharmacogenomics: Promises, Opportunities, and Limitations; Abstract; 1.1 Pharmacogenetics - The Roots of Pharmacogenomism; 1.2 Pharmacogenomics - It is Not just Pharmacogenetics; 1.2.1 Genetic Drug Response Profiles; 1.2.2 The Effect of Drugs on Gene Expression; 1.2.3 Pharmacogenomics in Drug Discovery and Drug Development; 1.3 Pharmacogenomics - Hopfe or Hype?; 1.4 References; 2 The Human Genome; Abstract; 2.1 Introduction 2.2 Expressed Sequence Tags (ESTs) and Computational Biology: The Foundation of Modern Genomic Science2.3 Microbial Genomics; 2.3.1 Computational Analysis of Whole Genomes; 2.3.2 Comparative Genome Analysis; 2.4 Genomic Differences that Affect the Outcome of Host-Pathogen Interactions: A Template for the Future of Whole-Genome-

Based Pharmacologic Science; 2.5 More Lessons from the Human Genome; 2.5.1 Protein-Coding Genes; 2.5.2 Repeat Elements; 2.5.3 Genome Duplication; 2.5.4 Analysis of the Proteome; 2.5.5 DNA Variation
2.6 Biological Complexity and the Role of Medicine in the Future of the Genome
2.7 Conclusion; 2.8 References; 3 Turning SNPs into Useful Markers of Drug Response; Abstract; 3.1 Introduction; 3.2 Two Approaches for Employing SNPs in Pharmacogenomics; 3.2.1 Candidate Gene Studies; 3.2.2 Whole Genome Linkage Disequilibrium Mapping Studies; 3.2.3 Comparison of Candidate Gene and Whole Genome LD Mapping; 3.3 How Many SNPs are Needed and What Kind are Useful for Pharmacogenomic Studies; 3.3.1 Location; 3.3.2 Frequency; 3.3.3 Haplotype Analysis
3.3.4 Number of SNPs Required for Whole Genome LD Mapping Studies
3.4 Study Designs for Pharmacogenomic Analysis; 3.4.1 Challenges Unique to Pharmacogenomics; 3.4.2 Clinical Trials, Case-Control and Cohort Studies; 3.5 Analytical Issues in Pharmacogenomic Studies; 3.5.1 Effect of LD on Sample Size; 3.5.2 Multiple Hypothesis Testing; 3.5.3 Gene-Drug Interaction; 3.6 Development of Pharmacogenomic Markers; 3.7 Conclusion; 3.8 References; 4 Association Studies in Pharmacogenomics; Abstract; 4.1 Introduction; 4.2 Variability and ADR in Drug Response: Contribution of Genetic Factors
4.3 Multiple Inherited Genetic Factors Influence the Outcome of Drug Treatments
4.3.1 Background; 4.3.2 Liver Metabolism Enzymes; 4.3.3 Transporters; 4.3.4 Plasma Binding Proteins; 4.3.5 Drug Targets; 4.4 Association Studies in Pharmacogenomics; 4.4.1 The Principles of Association Studies; 4.4.2 Study Design; 4.4.3 Direct Approach: A Hypothesis-Driven Strategy; 4.4.4 Indirect Approach: A Hypothesis-Generating Strategy; 4.5 SNP Assembly into Maps; 4.6 Strategies for Pharmacogenomic Association Studies; 4.6.1 Candidate Genes; 4.6.2 Genome-Wide Scan
4.7 Expected Benefits of Pharmacogenomics in Drug R & D

Sommario/riassunto

This is the very first comprehensive coverage of pharmacogenomics - a new discipline that will revolutionize health care. Pharmacogenomics leads to the understanding of the key genetic differences between individuals and will permit the individual tailoring of pharmacological treatments. Improved therapeutics can reach new levels by being able to differentiate between individuals according to their susceptibility to disease processes or adverse effects of medication. Pharmacogenomics also contributes to the discovery of new targets for drug development. Outstanding experts in the field p
